Geode Capital Management LLC Purchases 32,551 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Geode Capital Management LLC lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,683,500 shares of the medical equipment provider's stock after acquiring an additional 32,551 shares during the quarter. Geode Capital Management LLC owned approximately 2.42% of Lantheus worth $184,798,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its position in shares of Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock worth $393,844,000 after buying an additional 257,022 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock valued at $182,999,000 after buying an additional 796,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after buying an additional 19,071 shares during the last quarter. Swedbank AB raised its position in Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock valued at $79,266,000 after acquiring an additional 125,843 shares in the last quarter. Finally, Portolan Capital Management LLC lifted its stake in Lantheus by 6.1% in the third quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider's stock valued at $73,629,000 after acquiring an additional 38,776 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Redburn Atlantic assumed coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price on the stock. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. JMP Securities dropped their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a report on Thursday, November 7th. Finally, Truist Financial restated a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $130.00.

Lantheus Trading Up 0.5 %

NASDAQ:LNTH traded up $0.46 during mid-day trading on Monday, hitting $93.48. The company's stock had a trading volume of 838,558 shares, compared to its average volume of 1,012,044. The stock has a fifty day moving average of $97.88 and a 200-day moving average of $98.11. The company has a market capitalization of $6.50 billion, a price-to-earnings ratio of 15.42 and a beta of 0.45. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.